Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study

Masahiro Nakano1*, Atsunori Yorozu2, Shiro Saito3, Akitomo Sugawara4, Shinichiroh Maruo5, Shinsuke Kojima5, Takashi Kikuchi5, Masanori Fukushima5, Takushi Dokiya6 and Hidetoshi Yamanaka7

Abstract

Background: The incidence and associated factors of loose seed migration were investigated in cohort 1 of the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).

Methods: The study subjects were 2160 patients, consisting of 1641 patients who underwent permanent iodine-125 seed implantation (PI) and 519 patients who underwent PI combined with external beam radiation therapy (PI + EBRT). The presence or absence of seed migration to the chest and abdominal/pelvic region was determined.

Results: Seed migration was observed in 22.7% of PI group patients and 18.1% of PI + EBRT group patients (p = 0.0276). Migration to the lungs and abdominal/pelvic region was observed in 14.6% and 11.1% of the patients in the PI group, and 11.2% and 8.5% of the patients in the PI + EBRT group, respectively. In the PI group, the number of implanted seeds was associated with the seed migration incidence. Neither the PI nor the PI + EBRT group showed any difference in the volume of the prostate receiving 100% of the prescribed dose (V100 [%]) or the minimal dose received by 90% of the prostate volume (D90 [Gy]) between the patients with and without seed migration.

Conclusions: This prospective cohort study investigating the largest number of past cases showed no difference in D90 (Gy) or V100 (%) between seed migration or the absence thereof in both the PI group and PI + EBRT group.

Trial registration: ClinicalTrials.gov: NCT00534196

Keywords: Prostate cancer, Brachytherapy, Seed migration
Background
Transperineal permanent iodine-125 seed implantation (PI) for prostate cancer is widely accepted as a standard procedure for treating early-stage prostate cancer [1, 2]. It has shown favorable treatment outcomes [3, 4]. In Japan, treatment with iodine-125 (I-125) was introduced in July 2003 and is widely accepted [5, 6].

Seed migration is a well-known adverse event associated with PI. The seed migration incidence is reported to be 1.7–69.4 % [7–9]. There is a well-developed venous plexus around the prostate, and seeds are implanted near or within the veins. Thus, the seeds enter blood vessels and are transported by blood flow, which is considered to be the mechanism causing seed migration [10–13]. Various locations have been reported as sites of seed migration, including the lungs, abdomen, pelvic cavity, heart [14], vertebral venous plexus [15], kidneys [16], liver [17], and testicular veins [18]. As for the seed migration incidence, there are many reports of studies concerning only migration to the lungs, whereas only a few reports describe studies including migration to sites other than the lungs [9].

There is no report that comparatively investigates the incidence of seed migration by dividing between a PI group and PI combined with external beam radiation therapy (PI + EBRT) group. Past reports also had a small sample size of 20 to 495 cases that were investigated for migration. Thus, our investigation of the incidence of seed migration with PI and PI + EBRT was same. In PI cases, the prescribed radiation doses were set so that the values of the minimal dose received by 90 % of the prostate volume (D90) would be 144 Gy for the CTV. In the cases of PI + EBRT, the prescribed radiation doses were set so that the D90 values would be 100–110 Gy for the CTV, and the prescribed radiation doses in EBRT were set at 40–50 Gy, which was recommended to be delivered in 20–25 fractions. Post-planning was undertaken using CT scanning approximately one month after treatment. For pre- and post-planning, Interplant version 3.0 to 3.4, manufactured by CMS, or VarioSeed version 7.0 to 7.1, manufactured by VARIAN, software was used. I-125 seeds were loose seeds, and OncoSeed (Nihon Mediphysics) or Brachi source (Bird) was used and implanted using a Mick applicator (Mick TP 200 Mick Radio-Nuclear Instruments) in all patients [5].

Methods to evaluate seed migration
Seed migration was checked during a period from the following day to three months after PI. The presence or absence of migration to the lungs was checked by chest radiography (with a posterior-anterior [PA] view alone or PA and lateral [PA + lateral] views), and the presence or absence of migration to the abdomen or pelvis was checked with plain abdominal radiography except for only one institution (35 cases) checked with plain abdominopelvic CT. Patients were divided into the PI group (1641 patients) and the PI + EBRT group (519 patients) for assessment.

Methods

Methods to evaluate seed migration
Seed migration was checked during a period from the following day to three months after PI. The presence or absence of migration to the lungs was checked by chest radiography (with a posterior-anterior [PA] view alone or PA and lateral [PA + lateral] views), and the presence or absence of migration to the abdomen or pelvis was checked with plain abdominal radiography except for only one institution (35 cases) checked with plain abdominopelvic CT. Patients were divided into the PI group (1641 patients) and the PI + EBRT group (519 patients) for assessment.

Toxicity scoring and follow-up schedule
In order to grade adverse events associated with the rectum and urination conditions, the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 were used. Adverse events
were assessed at 3, 12, 24, and 36 months after PI, and the highest grade during this period was used for analysis [5].

Statistical analyses
Wilcoxon signed-rank test and chi-square analysis were used to determine the strength of the relationships between seed migration and clinical treatment parameters. A 0.05 level of statistical significance and confidence intervals with 95 % probability were set. Statistical analyses were performed using SAS statistical software (version 9.3, SAS Institute Inc., Cary, NS, USA). All statistical analyses were performed at the TRI [5].

Ethical considerations
This study was reviewed by the ethical review committee of each participating facility and conducted after written consent was obtained from patients [5].

Results
Methods and timeline of checking of seed migration
The methods used to evaluate seed migration were chest radiography with the PA view plus plain abdominal radiography in 1283 patients (59.4 %), chest radiography with the PA + lateral views plus plain abdominal radiography in 834 patients (38.6 %), and chest radiography with the PA view plus abdominal CT in 43 patients (2.0 %). The timeline of checking for seed migration was the day after implantation in 244 patients (11.3 %), one month after implantation in 1276 patients (59.0 %), and three months after implantation in 640 patients (29.6 %).

Incidence and sites of seed migration
Table 1 shows the patient characteristics stratified by the treatment strategies and the presence or absence of seed migration.

Out of all 2160 patients, 466 (21.6 %) showed seed migration. It was observed in 22.7 % (372/1641) of patients in the PI group and 18.1 % (94/519) of patients in the PI + EBRT group. Seed migration incidence in the PI group was significantly higher than that in the PI + EBRT group (p = 0.0276). Among patients with seed migration, the mean of migrating seeds per patient was 1.6 seeds (range, 1–9 seeds) in the PI group and 1.5 seeds (range, 1–5 seeds) in the PI + EBRT group. The number of migrating seeds was two seeds or less in 87.6 % in PI group and 86.2 % in PI + EBRT group. Migration to the lungs was observed in 14.6 % (240/1641) of PI group patients and 11.2 % (58/519) of PI + EBRT group patients. Moreover, migration to sites other than the lungs was observed in 11.1 % (182/1641) and 8.5 % (44/519) in the PI and PI + EBRT groups, respectively (Table 2).

The proportions of migrating seeds out of the total number of implanted seeds were 0.49 % in the PI group (120822 seeds implanted in total) and 0.53 % in the PI + EBRT group (26887 seeds implanted in total).

Within the PI group, the prostate volume (p = 0.0046) and the number of implanted seeds (p < 0.0001) were significantly larger in patients with seed migration than in those without seed migration (Table 1).

The Japanese national guideline recommends that total administered radionuclide activity be kept below 1300 MBq. Therefore, we had to reduce the prostate volume to around 30 cc with neoadjuvant androgen deprivation therapy (ADT) in case of PI monotherapy [6]. We presume that those may have been the reasons why the rate of patients treated with ADT was higher in the PI group than in the PI + EBRT group (Table 1).

When patients with seed migration were divided into those with seed migration confirmed on Day 1 and those with seed migration confirmed during a period from one to three months after implantation to assess the seed migration incidence, no significant difference was observed in either the PI or PI + EBRT group (Table 1).

Impact on radiation doses
In the PI group, no significant difference in the volume of the prostate receiving 100 % of the prescribed dose (V100 [%]) and D90 (Gy) values was observed between patients with and without seed migration (p = 0.7332 and p = 0.5866, respectively), whereas the values of volume of the prostate receiving 150 % of the prescribed dose (V150 [%]), the minimal dose received by 90 % of the urethral volume (UD90 [Gy]) and the minimal dose received by 5 % of the urethral volume (UD5 [Gy]) were significantly lower in patients with seed migration (p = 0.0184, p = 0.0258 and p = 0.0371, respectively). On the other hand, the PI + EBRT group showed no significant difference in these prescribed doses between patients with and without seed migration (Table 3). When the D90 (Gy) and V100 (%) values were analyzed by dividing patients in both the PI and PI + EBRT groups into three groups without seed migration, with one migrating seed, and with two or more migrating seeds, the values were significantly lower in the group with two or more migrating seeds compared to the group without seed migration (Fig. 1).

Planning and implant methods
Analysis according to planning methods revealed that, within the PI group, the seed migration incidence was significantly lower in patients receiving preplanning than in those receiving other planning methods (preplanning plus intraoperative planning). According to implantation methods, no significant difference was observed in either the PI or the PI + EBRT group (Table 1).
Table 1 Patient characteristics stratified according to the seed migration and treatment methods

|                      | PI Migration (−) (n = 1269) | Migration (+) (n = 372) | p*  | PI + EBRT Migration (−) (n = 425) | Migration (+) (n = 94) | p*  |
|----------------------|-----------------------------|--------------------------|-----|----------------------------------|------------------------|-----|
| Age: mean (median)   | 68.0 (69.0)                 | 67.4 (68.0)              | 0.1257 | 69.0 (70.0)                     | 68.4 (69.0)           | 0.3808 |
|                      | 45-89                       | 51-84                    |     | 52-88                           | 53-82                  |     |
| PSA (ng/mL): mean (median) | 7.1 (6.4)       | 7.2 (6.4)                | 0.9354 | 10.7 (9.3)                     | 10.8 (10.4)           | 0.7603 |
|                      | 1.6-41.8                    | 2.0-33.0                 |     | 1.9-42.0                        | 3.6-27.2              |     |
| BMI: mean (median)   | 23.6 (23.4)                 | 23.7 (23.7)              | 0.1524 | 23.5 (23.4)                     | 23.5 (23.3)           | 0.8588 |
|                      | 14.7-32.8                   | 17.9-32.1                |     | 15.5-35.7                       | 17.3-29.7             |     |
| Prostate volume (mL) | Mean (median)               | 26.2 (25.5)              | 0.0046 | 24.1 (23.4)                     | 25.1 (24.1)           | 0.2927 |
|                      | 73-71.0                     | 10.4-56.9                |     | 7.0-61.9                        | 11.0-60.9             |     |
| Number of seeds      | Mean (median)               | 72.6 (72.0)              | <0.0001 | 51.5 (50.0)                     | 53.2 (50.5)           | 0.1044 |
|                      | 34-120                      | 26-120                   |     | 25-85                           | 35-85                 |     |
| Number of migrated seeds | Mean (median)             | 1.6 (1.0)                |     | 1.5 (1.0)                       |                       |     |
|                      | -                           | 1-9                      |     | -                               | 1-5                   |     |
| Number of needles    | Mean (median)               | 22.9 (22.0)              | 0.1913 | 18.1 (17.0)                     | 18.4 (18.0)           | 0.3142 |
|                      | 10-45                       | 12-41                    |     | 9-36                            | 11-32                 |     |
| Planning methods     | Preplanning                 | 320                      | 0.1483 | 59                              | 11                    | 0.7385 |
|                      | Preplanning + intraoperative | 949                     | 312   | 366                             | 83                    |     |
| Loading methods      | Peripheral loading          | 229                      | 0.3308 | 35                              | 12                    | 0.2408 |
|                      | Modified peripheral loading | 1033                     | 313   | 384                             | 82                    |     |
|                      | Modified uniform loading    | 7                        | 3     | 6                               |                       |     |
| Androgen deprivation therapy | Yes                      | 699                      | 0.0174 | 117                             | 22                    | 0.4429 |
|                      | No                          | 569                      | 141   | 308                             | 72                    |     |
|                      | Unknown                     | 1                        | -     | -                               | -                     |     |
| Clinical T stage     | T1                          | 965                      | 0.1329 | 252                             | 48                    | 0.2662 |
|                      | T2                          | 295                      | 70     | 161                             | 42                    |     |
|                      | T3                          | 2                        | -      | 12                              | 4                     |     |
|                      | Unknown                     | 7                        | -      | -                               | -                     |     |
| Gleason score        | 6 or less                   | 873                      | 0.5907 | 62                              | 23                    | 0.0028 |
|                      | 7                           | 384                      | 108    | 312                             | 52                    |     |
|                      | 8 or more                   | 10                       | 1      | 51                              | 19                    |     |
|                      | Unknown                     | 2                        | 1      | -                               | -                     |     |
| Risk classification (D’Amico) | Low                    | 733                      | 0.9139 | 9                               | 4                     | 0.0419 |
Seed migration incidence stratified by methods of chest radiography
When patients were divided into those undergoing chest radiography with the PA view alone and those with the PA + lateral views for comparison, the PI group showed that the incidence of seed migration to the lungs was higher in patients undergoing chest radiography with the PA + lateral views than in those undergoing chest radiography with the PA view alone ($p = 0.0133$) (Fig. 2).

Seed migration incidence stratified by the time of study enrollment
When the seed migration incidence was compared by dividing the two-year study enrollment period into three phases of eight months (early, intermediate, and late), the PI group showed that the incidence was significantly lower in the intermediate and late phases than in the early phase ($p = 0.0224$ and $p = 0.0004$). In the PI + EBRT group, no significant difference was observed (Fig. 3).

Adverse events
The adverse events associated with the rectum and urination (NCI-CTCAE version 7.0) were divided into those below Grade 2 and those with Grade 2 or above for comparison. During the three years of the follow-up period, neither the PI nor PI + EBRT group showed any significant difference in the grades of adverse events between patients with and without seed migration.

Discussion
Around the prostate, there is a well-developed venous plexus. It is thought that seed migration occurs because seeds enter the veins and are transported by blood flow [12, 19]. The reported causes for seeds to enter the veins include direct implantation of seeds in the veins [19], an effect of intraabdominal pressure, posture, breathing, gravity, pubic arch interference, oblique needle insertion, number of seeds implanted, number of needles that induces seeds implanted near the veins to enter the veins [9, 18, 24, 28, 29], and edema occurring after implantation [8]. There are many reports describing that, especially when seeds are implanted in the extracapsular area or at the level inferior to the apex of the prostate, the seed migration incidence is high [12, 19]. However, there are also reports that implantation in the extracapsular area does not elevate the seed migration incidence [10, 30].

Table 1 Patient characteristics stratified according to the seed migration and treatment methods (Continued)

| Period of checking for migration | PI (%) | PI + EBRT (%) | $p^*$ |
|----------------------------------|--------|--------------|-----|
| Day 1                            | 164 (42) | 334 (63) | 0.4247 |
| 1-3 months                       | 1105 (330) | 396 (85) | 0.3806 |

*: Wilcoxon signed test for qualitative variables, Fisher’s Exact for quantitative variables

PI = permanent iodine-125 seed implantation; PI+EBRT = PI combined with external beam radiation therapy

Table 2 Location and number of migrated seeds stratified according to treatment methods

| Migration | PI (%) | PI + EBRT (%) | $p^*$ |
|-----------|--------|--------------|-----|
| Yes       | 372 (22.7) | 94 (18.1) | 0.0276 |
| No        | 1269 (77.3) | 425 (81.9) | |

*: Chi square test

PI = permanent iodine-125 seed implantation; PI+EBRT = PI combined with external beam radiation therapy
Definition of seed migration

Although the transfer of seeds out of the prostate is referred to as seed migration, only the transfer of seeds to the lung is regarded as seed migration in many cases. In the present study, seed migration was defined as “an event in which seeds enter a blood vessel and are transported out of the prostate by blood flow.” Thus, patients in whom seeds were shed into the seminal vesicles or bladder were not included in the group of patients with seed migration. In some of the past reports, movement of seeds within the seminal vesicles and the prostate was also defined as seed migration [20, 31]. Because the definitions vary among reports, the definitions should be checked before making any comparisons of the seed migration incidence.

Seed migration incidence

The seed migration incidence after PI using loose seeds is reported to range from 1.7 % to 69.4 % [8–13, 19–26] (Table 4). As for the seed migration incidence, there are many reports of studies concerning only migration to the lungs, but only a few reports have included migration to sites other than the lungs [9, 20, 29]. The incidence of seed migration to the lungs alone is reported to be from 1.7–55 %, and that of migration to sites other than the lungs is reported to range from 5.4–7.9 % (Table 4). When migration to the lungs is checked by chest radiography with the PA view alone, it has been reported that migration may be overlooked in 10–15 % of cases [10], and that seeds migrating to the vicinity of the diaphragm may be overlooked [19].

In our study, the overall seed migration incidence was 21.6 % (PI: 22.7 %, PI + EBRT: 18.1 %); the incidence of seed migration to the lung was 13.8 % (PI: 14.6 %, PI + EBRT: 11.2 %) and the incidence of seed migration to site other than lungs was 10.5 % (PI: 11.1 %, PI + EBRT: 8.5 %). These rates were comparable to those described in previous reports (Table 4). Our study included 1326 patients (61.4 %) who underwent chest radiography with the PA view alone and 834 patients (38.4 %) who underwent chest radiography with the PA + lateral views. The rate of detection of seed migration to the lungs by chest radiography with the PA + lateral views was higher than that by chest radiography with the PA view alone (Fig. 2); in patients undergoing chest radiography with the PA view alone, the incidence of seed migration to the lung might have been underestimated.

Moreover, in cases of seed migration to the heart, chest radiography may not be able to detect migrating seeds because of the heart rate [32]. Thus, CT is reportedly useful for identifying the accurate location of seeds migrating to the chest [14, 33]. However, performing chest CT for confirming migrations may increase the excess radiation exposure. Therefore, performing additional chest

| Table 3 Dosimetric comparison of migration or no migration |
|----------------------------------------------------------|
| Migration (−) | Migration (+) | p* |
| (n = 1269) | (n = 372) | |
| D90 (Gy) | | |
| Mean (median) | 161.1 (160.9) | 160.7 (159.8) | 0.5866 |
| Range | 78.0-231.9 | 86.4-223.7 |
| V100 (%) | | |
| Mean (median) | 93.7 (94.8) | 93.5 (94.9) | 0.7332 |
| Range | 63.6-100.0 | 56.3-100.0 |
| V150 (%) | | |
| Mean (median) | 62.6 (63.5) | 60.7 (60.7) | 0.0184 |
| Range | 20.8-94.6 | 18.4-91.6 |
| UD50 (Gy) | | |
| Mean (median) | 141.7 (142.5) | 138.2 (136.1) | 0.0258 |
| Range | 79.3-336.5 | 15.7-255.3 |
| UD5 (Gy) | | |
| Mean (median) | 228.6 (225.2) | 222.4 (218.7) | 0.0371 |
| Range | 119.0-427.0 | 125.9-338.2 |

*: Wilcoxon signed test for qualitative variable

D90 = minimal dose received by 90 % of the prostate volume; V100 = volume of the prostate receiving 100 % of the prescribed dose; V150 = volume of the prostate receiving 150 % of the prescribed dose; UD90 = the minimal dose received by 90 % of the urethral volume

UD5 = the minimal dose received by 5 % of the urethral volume; PI = permanent iodine-125 seed implantation

PI+EBRT = PI combined with external beam radiation therapy
CT should be indicated in cases where adverse events occur due to the migrated seeds.

In this study, seed migration to sites other than the lungs was observed in 10.5% of the patients. In several previous reports, only seed migration to the chest was assessed, whereas few have studied seed migration to sites other than the lungs [9] (Table 4). Seeds may migrate to sites other than the lungs in approximately 5.4–11% of the cases; thus, not only chest radiography (PA + lateral views) but also abdominal radiography should be performed simultaneously to accurately assess the seed migration incidence after PI [29]. Moreover, there is a report describing that the seed migration sites were confirmed by scintigraphy [8].

In the present study, we divided patients into the PI and PI + EBRT groups for analysis, finding that the seed migration incidence was higher in the PI group than in the PI + EBRT group (Table 1). This is the first report of a comparison between the PI and PI + EBRT groups.

Moreover, within the PI group, the prostate volume and the number of implanted seeds were significantly larger in patients with seed migration (Table 1). Some of the past studies also revealed that the number of implanted seeds is associated with the seed migration incidence [9, 24].

Furthermore, in the present study, the seed migration incidence was significantly lower, as the time of patient enrollment to cohort 1 of the J-POPS study was later (Fig. 3). This is assumed to reflect the effects of the learning curve through the accumulation of experience in the treatment procedure. Taussky et al. have also reported that the seed migration incidence was reduced as the learning curve increased [7].

Fig. 1 Dosimetric comparison of migration numbers. a. D90 (Gy), b. V100 (%) D90 (Gy) = minimal dose received by 90% of the prostate volume; V100 (%) = volume of the prostate receiving 100% of the prescribed dose; PI = permanent iodine-125 seed implantation; PI + EBRT = PI combined with external beam radiation therapy *: Wilcoxon signed-rank test
Timeline for evaluating seed migration

Because there are cases in which seed migration is not detected on the day of or after PI, but can be confirmed one month later, the seed migration incidence has often been reported to be higher at one month or more after implantation than on the following day [8, 10, 18, 20, 22]. Moreover, migrating seeds that are located in the pelvic cavity on the day after implantation may migrate to the lungs one month later [29]. Based on these reports, if the presence or absence of seed migration is checked only on the day of or after seed implantation, seed migration may be underestimated. Sugawara et al. have reported that the proportions of patients with confirmed seed migration were 13.9 % on the day after implantation, 22.8 % at 14 days after implantation, and 23.6 % at 3 months after implantation, showing an increase over time [18]. When loose seeds are used, the probability of new seed migration occurring one month or more after implantation is extremely low, and it seems appropriate to check seed migration one to three months after implantation instead of immediately after implantation [27]. In the present study, because patients with seed migration that was confirmed one to three months after implantation accounted for 88.6 %, seed migration was evaluated during the appropriate period in the majority of the patients. Although no difference in
| Authors         | Year | Number of patients | Numbers of P/PI + EBRT | Isotope                  | Percentage of patients with migration | Percentage of total seeds | Time of checking for migration |
|----------------|------|--------------------|------------------------|--------------------------|---------------------------------------|--------------------------|---------------------------------|
| Grimm et al.   | 1993 | 221/0              | I-125/Pd-103 (loose)  | 17.6                     | -                                     | -                        | 14.6 months                     |
| Nag et al.     | 1997 | 107/0              | Pd-103 (loose)        | 17.8                     | 0 (lung)                              | 1 month                  |
| Tapen et al.   | 1998 | 289/45             | I-125/Pd-103 (loose, linked) | 5.9 (loose 11.0, linked 0.7) | -                                     | 1 month                  |
| Merrick et al. | 2000 | 175/102            | I-125/Pd-103 (loose, linked) | 21.8 (loose 22.2, linked 21.4) | -                                     | <14 days, or >30 days        |
| Older et al.   | 2001 | 110/0              | Pd-103 (loose)       | 29.0                     | 0.22 (lung)                           | 1-16 months               |
| Ankem et al.   | 2002 | 58 Unknown         | I-125/Pd-103 (loose) | 36.2                     | 0.72 (lung)                           | 15-90 days (median 45 days) |
| Eshleman et al.| 2004 | 100/0              | I-125/Pd-103 (loose) | 55.0                     | 0.98 (lung)                           | 2-3 months                |
| Chauveinc et al.| 2004 | 170/0              | I-125 (loose)        | 16.0                     | 0.26 (lung)                           | 2 months                 |
| Kunos et al.   | 2004 | 120/0              | I-125/Pd-103 (loose) | 43.0                     | 0.54 (lung), 0.33 (pelvis)            | Median 133 days           |
| Fueller et al. | 2004 | 37/0               | I-125/Pd-103 (loose) | 24.0 (21.4)              | 0.193 (lung), 0.035 (pelvis)          | 3-12 months               |
| Stone et al.   | 2005 | 238/39             | I-125/Pd-103 (linked) | 0 (0)                    | 0                                     | 3-12 months               |
| Saibishkumar et al. | 2009 | 20/0               | I-125 (loose)        | 20.0                     | 0.23                                  | 1 month                  |
| Kono et al.    | 2010 | 62/0               | I-125 (linked)       | 0 (0)                    | 0                                     | 1 month                  |
| Sugawara et al.| 2011 | 267/2              | I-125 (loose)        | 22.2 (21.4)              | 0.36 (lung), 0.11 (abdomen + pelvis)  | Median 41 months          |
| Taussky et al. | 2012 | 495/0              | I-125 (loose)        | 10.3                     | 0.26 (lung), 0.58 (lung + others)      | 1 month                  |
| Miyazava et al.| 2012 | 121/5              | I-125 (loose)        | 0 (0)                    | 0.65 (total), 0.28 (lung), 0.34 (others) | 12 months                |
| Ishiyama et al.| 2014 | 66/0               | I-125 (loose)        | 30.0 (39.3 abdominopelvis) | 52*                                   | 1 month                  |
| J-POPS         | 2015 | 1641/0             | I-125 (loose)        | 14.6 (11.1)              | 0.49 (lung+others)                    | Day 1 to 3 months         |

*: Include lung, abdominopelvis, seminal vesicle and seed positioned more than 1cm from other seeds

I-125 = iodine-125; Pd-103 = palladium-103; J-POPS = Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation
PI = permanent iodine-125 seed implantation; PI+EBRT = PI combined with external beam radiation therapy
the seed migration incidence was observed between patients with seed migration confirmed on Day 1 and those with seed migration confirmed at one to three months after implantation, the incidence might have been underestimated in the former cases.

**Adverse events associated with seed migration**

The previously reported serious complications of migrating seeds include pneumonia [34], small cell lung cancer [35], myocardial infarction caused by seeds migrating into the coronary arteries [36], and neurological symptoms in the left lower extremity [37]. In the cases of migration into the coronary arteries, it is assumed that a right-to-left atrial or ventricular shunt existed [36]. The present study revealed no difference in adverse events (urination and gastrointestinal symptoms) according to the presence or absence of migrating seeds during the follow-up period, and no adverse events were observed at the sites of seed migration. Although the probability of occurrence of serious complications of seed migration can be expected to be extremely low, careful follow-up observation needs to be continued further in order to determine the presence or absence of an impact at the sites of seed migration.

**Impact on radiation doses**

Many of the past reports describe that there was no difference in D90 (Gy) values regardless of the presence or absence of seed migration [9, 23], whereas there are also reports that, with a large number of migrating seeds, V100 (%) and D90 (%) values tended to decrease [38–40]. In the present study, no impact on D90 (Gy) values was observed regardless of the presence or absence of seed migration (Table 3). However, when patients were divided into three groups of those without seed migration, with one migrating seed, and with two or more migrating seeds, the D90 (Gy) and V100 (%) values in the patients with two or more migrating seeds were significantly lower than that in patients without seed migration (Fig. 1). Despite the significant differences in D90 (Gy) values, the differences in the radiation doses were extremely small, and all three groups were exposed, on average, to the prescribed radiation doses or more. Thus, we assume that the impact on the treatment outcomes was small. However, if more seeds migrate, radiation doses will be insufficient, and treatment outcomes may be affected [40]. When insufficient radiation dose due to seed migration is apparent, reimplantation to the target site should be considered [41].

When loose seeds are used, implanting peripheral seeds within the prostate instead of the extraprostatic area is important to reduce seed migration [12, 23].

**Comparison between loose seeds and linked seeds**

Methods to reduce seed migration include the implantation of seeds in the capsule and the use of linked seeds. The incidence of migration of linked seeds reportedly ranges from 0 % to 35 %, which is lower than that of loose seeds [13, 23, 38, 42] (Table 4). Because linked seeds could not be used in Japan during the enrollment period of the J-POPS study, the seed migration incidence during this period cannot be compared between loose and linked seeds. In Japan, linked seeds became available in 2013, and since that time, there is a report that the incidence of the migration of linked seeds was lower than that of loose seeds [42]. With regards to radiation dose calculations, some reports describe that D90 (Gy) values were higher for linked seeds than for loose seeds [20, 39, 43], whereas other reports describe that no difference was observed [38, 42, 44, 45]. The opinions are divided. There is also another report that, although differences in D90 (Gy) values were observed between linked and loose seeds, no difference was observed in the seven-year recurrence-free rates based on prostate-specific antigen analysis [46]. Even if radiation doses are affected by the use of linked seeds, the impact on treatment outcomes can be expected to be extremely small. It has been reported that 30 days after treatment with linked seeds, a strand of four linked seeds migrated into the pelvic cavity [28], and that a strand of five linked seeds migrated out from the prostate 30 days after PI [31]. Even linked seeds may migrate into the veins. If linked seeds migrate as a strand, seeds implanted in the tract will migrate out from the prostate at one time, and there may be substantial impact on radiation doses. Moreover, linked seeds implanted in the extracapsular area may migrate when the vicryl sutures or spacers to which the seeds are attached are dissolved and absorbed. Thus, even if seed migration is evaluated on the day of implantation or one to three months after implantation, migration may not have yet occurred. When linked seeds are used, it should be considered to evaluate seed migration at a later time than when loose seeds are used [10, 12]. In clinical practice, when surgeons with techniques to implant loose seeds within the prostate perform implantation, the number of migrating seeds is two seeds or fewer in the majority of the cases, and the impact on D90 (Gy) values is small. However, further long-term follow-up studies are necessary to determine whether seed migration affects treatment outcomes.

**Limitation**

In the present multi-institutional study, implantation was usually performed by a different urologist for each facility, and treatment planning was usually conducted by a different radiologist for each facility. Because of the differences among the facilities in terms of the treatment...
experience of the doctors, radiation dose calculation software, prescribed radiation doses, methods to evaluate seed migration, methods to implant seeds, time of evaluating seed migration, the seed migration incidence varies among the facilities and may be underestimated.

Despite the limitations described above, the results of the present study appear to reflect the current state of the seed migration incidence after treatment with 1-125 loose seeds in Japan.

However, because this study had a short follow-up period, long-term follow-up observation is needed in the future to investigate whether adverse events occur at sites of seed migration or how treatment outcomes are affected.

Conclusions

The seed migration incidence was 21.6 % (PI: 22.7 %, PI + EBRT: 18.1 %), and it was higher in the PI group. In the PI group, the seed migration incidence was higher in those patients with a larger number of implanted seeds. Although there was no difference in D90 (Gy) and V100 (%) values between patients with and without seed migration in the both PI and PI + EBRT groups, the V150 (%), UD90 (Gy), and UD5 (Gy) values were significantly lower in patients with seed migration in the PI group. Thus, when the number of migrating seeds is large, radiation doses may be affected. Moreover, because migration to sites other than the lungs was observed in 10.5 % (PI: 11.1 %, PI + EBRT: 8.5 %), but also abdominal or pelvic radiography as well as chest radiography should be performed to check for seed migration. Additionally, patients who receive PI should be provided with a sufficient explanation of the possible seed migration before treatment.

To the best of our knowledge, this is the first reported prospective cohort study on I-125 loose seed migration, and investigates a record number of cases. It is also the first report to compare the incidence of migration between a PI group and a PI + EBRT group.

Abbreviations

PI: Permanent Iodine-125 seed implantation; EBRT: External beam radiation therapy; PI + EBRT: Permanent seed implantation combined with external beam radiation therapy; I-125: Iodine-125; J-POPS: Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation; ABS: American Brachytherapy Society; TRI: Translational Research Informatics Center; CT: Computed tomography; CTV: Clinical target volume; PA: Posterior-anterior; NCI-CTCAE: the National Cancer Institute Common Terminology Criteria for Adverse Events; D90: The minimal dose received by 90 % of the prostate volume; UD90: The minimal dose received by 90 % of the urethral volume; UD5: The minimal dose received by 5 % of the urethral volume; V100: Volume of the prostate receiving 100 % of the prescribed dose; V150: Volume of the prostate receiving 150 % of the prescribed dose; PSA: Prostate specific antigen; BMI: Body mass index; PI-103: Palladium-103; ADT: Androgen deprivation therapy.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MN participated in the design of the study, analysis and interpretation of data and drafted the manuscript. AY conceived of the study, participated in the design of the study and coordination and helped to draft the manuscript. SS conceived of the study, participated in the design of the study and coordination of the study. AS participated in the design of the study and helped to draft the manuscript. SM, SK and TK performed the statistical analysis and helped to draft the manuscript. MF made substantial contribution to conception and design of the study. TK and HY conceived of the study, participated in the design of the study and coordination of the study. All authors read and approved the final manuscript.

Author details

1Department of Urology, Gifu University Graduate School of Medicine, 1-1Yanagito, Gifu-shi, Gifu 501-1194, Japan. 2Department of Radiation Oncology, National Hospital Organization, Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. 3Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. 4Department of Radiation Oncology, Tokai University, Hachioji Hospital, 1838 Iikawa-machi, Hachioji-shi, Tokyo 192-0032, Japan. 5Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo 650-0047, Japan. 6Department of Radiology, Kyoto University Hospital, 1-8 Kandasunagadai, Chiyoda-ku, Tokyo 102-0062, Japan. 7Institute of Preventive Medicine, Kurosawa Hospital, 187 Yanakakami, Takasaki-shi, Gunma 370-1203, Japan.

Received: 5 July 2015 Accepted: 28 October 2015

Published online: 14 November 2015

References

1. NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate cancer, Version 1). 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–37.
3. Criz FA, Benton JB, Shlake P, Merlin ML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol. 2013;189:78–83.
4. Grimm P, Billiet J, Bostwick D, Dicker AP, Frank S, Immerezel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group. BJU Int. 2012;109 Suppl 1:22–9.
5. Saito S, Ito K, Yorozu A, Aoki M, Koga H, Satoh T, et al. Nationwide Japanese prostate cancer outcome study of permanent Iodine-125 seed implantation (J-POPS). Int J Clin Oncol. 2015;20:375–85.
6. Yorozu A, Kurova N, Takahashi A, Toya K, Saito S, Nishiyama T, et al. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients. Brachytherapy. 2015;14:111–7.
7. Tausky D, Moundjian C, Larouche R, Belliveau-Nadeau D, Boudreau C, Hervieux Y, et al. Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy. 2012;11:452–6.
8. Kono Y, Kubota K, Aruta T, Ishibashi A, Morooka M, Ito K, et al. Swelling of the prostate gland by permanent brachytherapy may affect seed migration. Jap J Clin Oncol. 2010;40:159–65.
9. Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Seki S, et al. Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125I) seeds. Radiat Oncol. 2011;6:130.
10. Merrick GS, Butler WM, Dorsey AT, Lief JH, Benson ML. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2001;46:215–20.
11. Older RA, Synder B, Krupski TL, Glenmbock DJ, Gillenweber JY. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol. 2001;165:1590–2.
12. Stone NN, Stock RG. Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy. Urology. 2005;66:119–23.
13. Salibthikumar EP, Borg J, Yeung L, Cummins-Holder C, Landon A, Crook J. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:618–9.

14. Matsuo M, Nakano M, Hayashi S, Ishihara S, Maeda S, Uno H, et al. Prostate brachytherapy seed migration to the right ventricle: chest radiographs and CT appearances. Eur J Radiol. 2007;67:91–3.

15. Nakano M, Uno H, Gotot T, Kubota Y, Ishihara S, Deguchi T, et al. Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy. 2006;5:127–30.

16. Nguyen BD, Schild SE, Wong WW, Vora SA. Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy. 2009;8:309–12.

17. Nguyen BD. Cardiac and hepatic seed implant embolization after prostate brachytherapy. Urology. 2006;68:673.e17–673.e19.

18. Sugawara A, Nakasima J, Kunieda E, Nagata H, Mizuno R, Seki S, et al. Prostate brachytherapy seed migration to a left varicocele. Brachytherapy. 2012;11:502–6.

19. Eshleman JS, Davis BJ, Pinskey TM, Wilson TM, Haddock MG, King BF, et al. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extrastatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004;59:419–25.

20. Fuller DB, Koziol JA, Feng AC. Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy. 2004;3:10–9.

21. Grimm PD, Ragde H, Sylvester J, Mate T. Migration of iodine-125 and palladium-103 seeds to the lung after transperineal brachytherapy for prostate cancer. Endocurc Hypertherm Oncol. 1993;59:10.

22. Nag S, Vivekanandam S, Martinez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39:667–70.

23. Tapen EM, Blasko JC, Grimm PD, Ragde H, Luse R, Clifford S, et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. J Radiat Oncol Biol Phys. 1998;42:1063–7.

24. Ankem MK, DeCarvalho VS, Harangozo AM, Hartanto VH, Perrotti M, Kr H, et al. Implications of radioactive seed migration to the lungs after prostate brachytherapy. Urology. 2002;59:555–9.

25. Chauveinc L, Osseili A, Flam T, Thiounn N, Rosenwald JC, Savignoni A, et al. Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients. Cancer Radiot. 2004;8:211–6.

26. Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ. Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy. 2004;3:71–7.

27. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for permanent transperineal brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–99.

28. Dedic-Hagan J, Teh AY, Liang E, Collett N, Woo HH. Migration of a strand of 125I radioactive seed from the prostate gland into the right ventricle: Radiation pneumonitis caused by a migrated brachytherapy seed lodged in the lung. J Clin Oncol. 2008;26:623–5.

29. Shen WC, Katcher J, Nunez C, Tirgan AM, Ellis RJ. Radioactive seed migration after transperineal intrstitial prostate brachytherapy and associated development of small-cell lung cancer. Brachytherapy. 2012;11:534–8.

30. Zhu AX, Wallner KE, Frinold GP, Ferry D, Jutzy KR, Foster GP. Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy. 2006;5:262–5.

31. Hau EK, Oborn BM, Bucc J. An unusual case of radioactive seed migration to the vertebral venous plexus and renal artery with nerve root compromise. Brachytherapy. 2011;10:295–8.

32. Reed DR, Wallner KE, Merrick GS, Anthor S, Muller A, Cavanagh W, et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy. 2007;6:129–34.

33. Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB. Radioactive seed migration after prostate brachytherapy with iodine-125 using loose seeds versus stranded seeds. Int Braz J Urol. 2009;35:573–80.

34. Gao M, Wang LZ, Nag S, Gupta N. Effects of seed migration on post-implant dosimetry of prostate brachytherapy. Med Phys. 2007;34:471–80.

35. Di Muzio N, Longobardi B, Losa A, Mangilli P, Nava LD, Rigatti P, et al. Seed migration in prostate brachytherapy: a re-implant case report. Brit J Radiol. 2003;76:913–5.

36. Ishiyama H, Satoh T, Kawaikami S, Tsumura H, Komori S, Tabata K, et al. A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2014;90:134–9.

37. Fagundes HM, Keys RJ, Wojcik MF, Radden MA, Bertelsman CG, Cavanagh WA. Transperineal TRUS-guided prostate brachytherapy using loose seeds versusRAPIDStrand: a dosimetric analysis. Brachytherapy. 2004;3:136–40.

38. Zauli A, Astenafi MS, Oniscu G, Clarke HS, Marshall DT. Comparison of intraoperatively built custom linked seeds versus loose seed gun applicator technique using real-time intraoperative planning for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2011;81:1010–6.

39. Kaplan ID, Meskel PM, Lieberfarb M, Saltzman B, Berg S, Holupka EJ. A comparison of the precision of seeds deposited as loose seeds versus suture embedded seeds: a randomized trial. Brachytherapy. 2004;3:7–9.

40. Herbert C, Morris WJ, Hammar J, Lapointe V, McKenrole M, Pickles T, et al. The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy. Brachytherapy. 2011;10:442–8.